---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030764"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:06:24.246342+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR

## Summary
- Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.
- LP-300 Harmonic Phase 2 lead-in (7 pts): 86% clinical benefit rate, 43% objective response rate, no dose-limiting toxicities.
- LP-184 Phase 1A: 7 cohorts dosed, no DLTs; LP-284 third cohort dosing, no DLTs; both on track.
- RADR platform collaboration with Oregon Therapeutics for XCE853; Starlight Therapeutics advancing STAR-001 for recurrent GBM.
- Japanese patent issued for LP-284; Webinar Wednesdays launched for AI and oncology.

## SEC filing metadata
- accession: 0001493152-24-030764
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315224030764/0001493152-24-030764-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315224030764/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030764
- JSON: https://secwatch.observer/filing/0001493152-24-030764.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030764.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.